Following yesterday's announcement by Sanofi-Aventis and Bristol-Myers Squibb that they had successfully defended their patent on the blood thinner Plavix, the analysts quickly revived speculation that the French pharma company could revive an effort to buy BMS. Internal dissension at Sanofi, though, coupled with a high valuation for Bristol-Myers Squibb is giving the analysts some pause, however.
- see this release for more on the patent
- read the Financial Times report
More details emerge on secret Plavix pact. Report
Rumor Mill: Is BMS going on the sales block? Report
Analysts buzzing about possible Bristol-Myers sale. Report
Sanofi says no charges on Plavix. Report